BusinessGranules Seeks 180-Day Exclusivity for Generic Ruxolitinib in U.S.
Granules has filed for Paragraph IV certification concerning patents listed in the U.S. FDA's Orange Book for the generic cancer drug Ruxolitinib. The company has also issued the required notice to relevant parties as per U.S. regulatory rules, aiming to be the first to file and secure 180 days of market exclusivity in the United States.
Hindu Business·




